Stocksigma LogoStocksigma Logo

Beryl Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh)

■ Revenue: 693 (+35.4% YoY | -5.0% QoQ) ■ EBITDA: 23.9 (-65.6% YoY | -36.7% QoQ) ■ EBITDA Margin (%): 3.5 (-1013 bps YoY | -173 bps QoQ) ■ PAT: 5.7

Beryl Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh)

Beryl Drugs Ltd · Financial Result · 14 Nov 2026, 9:38 pm

Beryl Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 693 (+35.4% YoY | -5.0% QoQ) ■ EBITDA: 23.9 (-65.6% YoY | -36.7% QoQ) ■ EBITDA Margin (%): 3.5 (-1013 bps YoY | -173 bps QoQ) ■ PAT: 5.7 (+537.1% YoY | -74.3% QoQ) ■ EPS (INR): 0.11 (+450.0% YoY | -75.0% QoQ)

Original exchange filing (PDF)

More announcements from Beryl Drugs Ltd

All Beryl Drugs Ltd announcements